Abstract
Vemurafenib is a specific inhibitor of the V600E mutated BRAF protein kinase used for the treatment of unresectable or metastatic melanoma harboring this mutation. Multiple predictable side effects have been described with use of this targeted therapy, and implicate BRAF and mitogen activated protein kinase (MAPK) signaling pathways in their pathogenesis. Herein, we report the novel finding of an interface dermatitis in radiation recall and a keratosis pilaris-like clinical reaction in a patient treated with vemurafenib.
Original language | English (US) |
---|---|
Pages (from-to) | 539-543 |
Number of pages | 5 |
Journal | Journal of cutaneous pathology |
Volume | 41 |
Issue number | 6 |
DOIs | |
State | Published - Jun 2014 |
Externally published | Yes |
Keywords
- dermatopathology
- melanoma
- radiation therapy
ASJC Scopus subject areas
- Pathology and Forensic Medicine
- Histology
- Dermatology